NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

NCT06086340

CompletedN/A

Sponsor: Pfizer

Conditions: Breast Cancer

Interventions: Palbociclib, Aromatase Inhibitor

Countries: United States

A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy alone treatment in women or men aged 65 and older with newly diagnosed hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States

Eligibility overview

Sex: ALL

Age: 65 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* De novo metastatic (stage IV) disease at initial breast cancer diagnosis during 2015-2019
* HR+/HER2- molecular subtype at diagnosis
* Initiated 1L systemic therapy with palbociclib + AI or AI alone

Exclusion Criteria:

* Patients will be excluded if their metastatic breast cancer diagnosis was first recorded in a death certificate or at the time of autopsy.

Locations (1)

New York, New York, United States